Cytomegalovirus infection after allogeneic stem cell transplant in children
- 14 October 2005
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (6) , 734-740
- https://doi.org/10.1111/j.1399-3046.2005.00370.x
Abstract
The aim of this study was to examine the frequency and the course of cytomegalovirus (CMV) infection and CMV disease in a group of pediatric and adolescent patients after allogeneic stem cell transplantation. Patients were treated according to a protocol including prophylactic high-dose acyclovir in combination with preemptive administration of ganciclovir, based on weekly examinations of CMV antigenemia. A total of 110 consecutively transplanted patients, with a mean age of 9 yr (range 0-20) were treated according to the protocol. All patients were transplanted between March 1993 and January 2000 at the only Danish allotransplantation center. CMV infection occurred in 21.8% (24 of 110) of the patients. Three patients [12.5% (3/24)] developed CMV disease, all with pneumonitis and one with gastrointestinal disease as well. Mean time of disease onset was day +58. Treatment with ganciclovir was in general well tolerated. Late onset CMV disease was not documented. Multivariate analysis revealed that the use of unrelated donor transplants was significantly associated with an increased risk for CMV infection [hazard ratio (HR) 2.90, p = 0.03] and CMV infection was found to be a risk factor for transplant related mortality before day +100 (HR 10.70, p = 0.0015). Although high-dose acyclovir in combination with antigenemia based preemptive treatment with ganciclovir resulted in a low incidence of CMV disease in pediatric and adolescent patients, CMV infection was a significant risk factor in stem cell transplantation with unrelated donors.Keywords
This publication has 25 references indexed in Scilit:
- High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantationBone Marrow Transplantation, 2004
- Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood productsBlood, 2003
- Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortalityBone Marrow Transplantation, 2003
- Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunityBlood, 2003
- Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemaia on Patients' outcomeBritish Journal of Haematology, 1994
- Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantationThe Lancet, 1994
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991
- VARIABLES PREDICTING BACTERIAL AND FUNGAL INFECTIONS AFTER ALLOGENEIC MARROW ENGRAFTMENTTransplantation, 1987
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974